Valneva Engages Investors at Major Healthcare Conferences
Valneva Engages Investors at Major Healthcare Conferences
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA) is an innovative specialty vaccine company making strides in combating infectious diseases. Recently, the company announced that its senior management team will engage with institutional investors in upcoming healthcare conferences across the United States and Europe. These events present a unique opportunity for Valneva to showcase its commitment to advancing immunization strategies and provide insight into its potential economic impact.
Fireside Chats and Key Discussions
During these conferences, Valneva will host moderated fireside chats, where management will delve into the company’s strategic value drivers and anticipated advances, particularly focusing on the pivotal Phase 3 trial outcomes for VLA15, its Lyme disease vaccine candidate. This candidate is notable because Valneva is partnering with Pfizer, a formidable player in the vaccine field. An approval process could potentially lead to a launch in 2027, and expectations are high for this critical development.
Upcoming Conference Details
Valneva's schedule leading up to these investor meetings features key events:
- Guggenheim 2nd Annual Healthcare Innovation Conference
Date/Time: November 10, 10:30 AM EST | Location: Boston, Massachusetts - Stifel 2025 Healthcare Conference
Date/Time: November 11, 9:20 AM EST | Location: New York, New York - Jefferies London Healthcare Conference
Date/Time: November 19, 2:00 PM GMT | Location: London, United Kingdom
Investor Participation
Institutional investors interested in meeting with Valneva management can coordinate requests through their banking representatives, ensuring a fruitful dialogue tailored to investment opportunities and comprehensive updates on the company's direction.
About Valneva SE
Valneva SE operates at the forefront of vaccine innovation, developing key prophylactic vaccines tailored to address critical, unmet medical needs. The company’s targeted approach leverages extensive expertise across various vaccine modalities. Valneva's successful advancement of multiple vaccines from initial research to market approval underscores its strong track record and commitment to improving global health outcomes.
The ongoing development of VLA15 represents a significant milestone for Valneva, as it is the only Lyme disease vaccine candidate that has reached advanced clinical trials. Additionally, the company is progressing on innovative candidates targeting Shigella and other global health concerns.
Valneva's Commitment to Growth
Valneva’s expanding portfolio not only reflects its strong scientific capabilities but also its dedication to addressing public health challenges. Revenues from existing commercial operations foster the continued progress of its vaccine pipeline, reiterating Valneva’s commitment to tapping into innovative vaccine solutions.
Contact Information for Investor Relations
For further inquiries regarding investor relations, Valneva's dedicated contacts are:
- Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M: +33 (0)6 4516 7099
Email: laetitia.bachelotfontaine@valneva.com - Joshua Drumm, Ph.D.
VP, Global Investor Relations
M: +001 917 815 4520
Email: joshua.drumm@valneva.com
Frequently Asked Questions
What is the significance of Valneva's participation in these conferences?
Valneva's participation allows the company to directly engage with investors, offering insights into its current projects, especially the development of its Lyme disease vaccine candidate, VLA15.
What is VLA15?
VLA15 is Valneva's Lyme disease vaccine candidate that is currently in Phase 3 trials, representing a potential breakthrough in Lyme disease prevention.
Who is Valneva partnered with for the development of VLA15?
Valneva is partnering with Pfizer to develop and potentially commercialize the VLA15 vaccine.
When is the expected market launch for the vaccine?
If successful in trials and approved, the vaccine could be launched in the second half of 2027.
How can investors communicate with Valneva management?
Investors can schedule meetings with Valneva management by contacting their representatives at their respective banks ahead of the conferences.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
